On Wednesday, ASML Holding NV (ADR) (NASDAQ:ASML)’s shares declined -3.83% to $96.14.
ASML Holding NV (ADR) (ASML) publishes its 2015 first-quarter results.
- Q1 net sales of EUR 1.65 billion, gross margin 47.2 percent
- ASML guides Q2 2015 net sales at around EUR 1.6 billion and a gross margin of around 45 percent
CEO Statement
“Our first-quarter net sales came in as guided at 1.65 billion euros, driven by continued strong DRAM memory segment sales in combination with higher foundry segment sales. Our gross margin rose to 47.2 percent, a reflection of product mix in addition to better utilization of our production facilities, which was partly offset by unfavorable foreign exchange effects. Our Q2 guidance of around 1.6 billion euros of net sales confirms our earlier expectation that the first half of 2015 will be stronger than the second half of 2014.
Q1 Product Highlights
Exposed more than 1000 wafers in a 24-hour period on a NXE:3300B.
EUV source power upgrade is being rolled out to multiple customer sites.
Our Overlay and Focus Package for the TWINSCAN NXT:1970Ci, which improves focus uniformity by up to 30 percent and matched machine overlay by more than 30 percent, practiced good adoption by logic customers.
ASML Holding N.V. engages in the development, production, marketing, sale, and servicing of advanced semiconductor equipment systems with a focus on lithography related systems worldwide. It provides PAS 5500 family products, which comprise wafer steppers, and step and scan systems with i-line, krypton fluoride, and argon fluoride light sources for processing wafers.
Precision Castparts Corp. (NYSE:PCP)’s shares dropped -3.65% to $208.08.
Precision Castparts Corp. (PCP) declared that following a review of its oil & gas and power pipe end markets and inventories, the Company will recognize fiscal fourth quarter 2015 charges for actions taken to rationalize certain assets and restructure operations. The Company saw continued demand deterioration in its oil & gas and power pipe markets through the fourth quarter of fiscal 2015 and is taking aggressive action to improve its cost and capacity position, counting the exit of non-essential investments.
The Company will recognize a non-cash impairment charge in the range of $210 million to $220 million pre-tax related to its 50% ownership interest in Yangzhou Chengde Steel Tube Co., Ltd. (Chengde) as it pursues a sale of that stake. In addition, PCC will recognize a non-cash inventory and other asset impairment charge in the range of $125 million to $135 million pre-tax, primarily in its oil & gas, power pipe and associated raw material operations, reflecting the more challenging market environment, declines in market value, and size or quality characteristics that influence marketability. Both impairments are to be recognized in the fourth quarter of fiscal 2015 in conjunction with the Company’s planned rationalization plans.
Precision Castparts Corp. manufactures and sells metal components and products worldwide. It operates in three segments: Investment Cast Products, Forged Products, and Airframe Products. The Investment Cast Products segment manufactures investment castings for aircraft engines, industrial gas turbine (IGT) engines, airframes, medical implants, armament, unmanned aerial vehicles, and other industrial applications.
At the end of Wednesday’s trade, Exelixis, Inc. (NASDAQ:EXEL)‘s shares dipped -3.42% to $3.11.
Exelixis, Inc. (EXEL) declared that its first quarter 2015 financial results will be released on Thursday, April 30, 2015 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis administration will host a conference call to talk about the results and provide a general business update. The conference call will be accessible via the Internet from the Company’s website.
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
NuVasive, Inc. (NASDAQ:NUVA), ended its Wednesday’s trading session with -3.28% loss, and closed at $43.59.
NuVasive, Inc. (NUVA) declared that its first quarter 2015 earnings declaration will take place on Monday, May 4, 2015 after the close of the market.
NuVasive will hold a conference call on Monday, May 4, 2015 at 4:30 p.m. ET / 1:30 p.m. PT to talk about the results of its financial performance in the first quarter 2015. The dial-in numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers.
NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
